You are here: Industry Insights > Sun Pharma

News List

Sun Pharma's New Jersey manufacturing overhaul puts 96 jobs at risk pharmafile
November 28, 2018
Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to “improve cost efficiencies, it has emerged – a move which puts almost 100 jobs at risk.
Sun gets dermatology portfolio, two plants in Japan with Pola Pharma deal expressbpd
November 27, 2018
Acquisition to help in building global dermatology business
Sun Pharma to acquire Japan’s Pola Pharma through arm financialexpress
November 27, 2018
Sun Pharma forayed into the Japanese prescription market in 2016 with the acquisition of 14 established prescription brands from Novartis.
Sun Pharma to acquire Pola Pharma in Japan expressbpd
November 26, 2018
Sun Pharmaceutical Industries including its subsidiaries and/or associate companies, announced that Sun Pharma has entered into a definitive agreement to acquire Pola Pharma, a Japanese pharmaceutical company engaged in research and development, manufactu
Sun Pharma posts net profit of ₹ 996 crores at Q2FY19 expressbpd
November 15, 2018
In H1FY19,the company’s sales / income from operations was at ₹ 13,985 crores
Samsung BioLogics’ End-to-End service to maximize client satisfaction cphi-online
November 14, 2018
Samsung BioLogics was established in April 2011, and is headquartered in Incheon, South Korea. Samsung BioLogics provides an end-to-end service for contracted biopharmaceutical
Sun Pharma bags receipt of European Commission approval expressbpd
September 20, 2018
The drug ILUMETRI (tildrakizumab) is indicated for the treatment of adults with moderate-to-severe chronic plaque psoriasis
Sun Pharma, SPARC Announce FDA Approval of Xelpros americanpharmaceuticalreview
September 18, 2018
Sun Pharmaceutical and Sun Pharma Advanced Research Company (SPARC) announced U.S. Food and Drug Administration (FDA) approval...
Sun Pharma, SPARC announce FDA approval of Xelpros financialexpress
September 17, 2018
Xelpros (latanoprost ophthalmic emulsion) 0.005 per cent for topical ophthalmic use is the first and only benzalkonium chloride-free (BAK-free) form of latanoprost
Sun Pharma’s Mohali plant on FDA radar financialexpress
September 13, 2018
Recently, the USFDA had issued Form 483 with six observations related to deficient procedures after an inspection of the company’s Halol facility in Gujarat

Previous page 1 2 3 4 5 6 7 8 9 Next page